Helsinn

Helsinn is a global pharmaceutical company, headquartered in Lugano, Switzerland, founded in 1976 by Dr. Gabriele Braglia. This third-generation family-owned firm specializes in supportive care products, enhancing the well-being of patients with cancer and chronic diseases, particularly addressing side effects like chemotherapy-induced nausea and vomiting. Helsinn licenses, develops, manufactures, and commercializes its treatments through an integrated licensing model with long-standing partners, reaching patients in 90 countries worldwide. Originally a licensing business, it has strategically expanded into oncology therapeutics and broader chronic disease management, establishing itself as a fully integrated pharmaceutical firm. Key figures include CEO Riccardo Braglia and board member Paolo Guainazzi. The company also operates a USD 50 million Helsinn Investment Fund, reflecting its strong commitment to innovation and strategic growth, and was previously estimated to be a $350 million firm.